1. Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
   Takumi Hirata et al, 2013, International Journal of Endocrinology CrossRef
2. VII. The Evidence of Pharmacologic Treatment for NASH
   Masashi Yoneda, 2020, Nihon Naika Gakkai Zasshi CrossRef
3. Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
   Carolina M. Perdomo et al, 2021, Journal of Clinical Medicine CrossRef
4. Angiotensin II type 1 receptor (AT1) blockade by Telmisartan attenuates hepatic steatosis in high-fat fed mice reducing Resistin, TRL4, and Myd88 expression
   Luciana Mendes Araújo Borém et al, 2022, Egyptian Liver Journal CrossRef
5. Metabolic Disorders and Steatosis in Patients with Chronic Hepatitis C: Metabolic Strategies for Antiviral Treatments
   Munechika Enjoji et al, 2012, International Journal of Hepatology CrossRef
6. Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
   Juan M. Saavedra, 2021, Physiology CrossRef
7. Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
   Jose Arriola-Montenegro et al, 2023, World Journal of Cardiology CrossRef